Replies to post #112814 on Savvy Trades and Investments

[RNsidersbuying]

VNDA 5.06 - filed Q1 yesterday afternoon with following CC and the pps actually dipped? With this dip, VNDA is now my largest position in quite a while.

From the CC:

Mihael Polymeropoulos

...We expect several significant milestones in the coming months, including the launch of Fanapt in bipolar I disorder, the launch of PONVORY in multiple sclerosis, the potential approval of tradipitant in gastroparesis, the Phase III results of tradipitant in motion sickness, the upcoming NDA filings of milsaperidone in psychiatric disorders and tradipitant motion sickness and the initiation of clinical programs in depression, psoriasis, ulcerative colitis and pediatric insomnia.

We are confident that our robust revenue, strong cash position and efficient operations position us well for significant growth and value creation in the years to come...

https://capedge.com/transcript/1347178/2024Q1/VNDA

[RNsidersbuying]

XLO 1.08 - adding here. GILD recently bought 6.8M shares at $1.97...pretty sure GILD knows more about this company than I do?

Item 8.01. Other Events.

As previously disclosed, in connection with Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the “Company”), entering into an exclusive license agreement with Gilead Sciences, Inc. (“Gilead”), on March 27, 2024, the Company entered into a stock purchase agreement with Gilead pursuant to which the Company agreed to, among other things, initially issue and sell 6,860,223 shares (the “Gilead Shares”) of its common stock, $0.0001 par value per share (the “Common Stock”), to Gilead in a private placement at a purchase price of $1.97 per share, for an aggregate purchase price of approximately $13.5 million (the “Initial Gilead Private Placement”). The Initial Gilead Private Placement closed on March 28, 2024.

As of March 25, 2024, the Company had 27,613,263 shares of Common Stock outstanding. Following the issuance of the Gilead Shares upon the closing of the Initial Gilead Private Placement on March 28, 2024, the Company had 34,473,486 shares of Common Stock outstanding.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318197772&type=HTML&symbol=XLO&cdn=791e81ebc11336b13f045aa98b2d415c&companyName=Xilio+Therapeutics+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-03-28